Mga Batayang Estadistika
| CIK | 1613170 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Itamar Medical Ltd
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2022 |
PAYX / Paychex, Inc. / Viola Growth Management Fund 2 Ltd. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (including Ordinary Shares represented by American Depositary Shares, |
|
| February 11, 2022 |
PAYX / Paychex, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| December 27, 2021 |
15-12B 1 tm2136338d115-12b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38775 Itamar Medical Ltd. (Exact n |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT NO. 333-250155 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT NO. 333-252364 UNDER THE SECURITIES ACT OF 1933 ITAMAR MEDICAL LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into Engl |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230799 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-236883 UNDER THE SECURITIES ACT OF 1933 ITAMAR MEDICAL LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into Engl |
|
| December 16, 2021 |
POS AM 1 tm2135602d3posam.htm POS AM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT NO. 333-250155 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT NO. 333-252364 UNDER THE SECURITIES ACT OF 1933 ITAMAR MEDICAL LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Trans |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230799 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-236883 UNDER THE SECURITIES ACT OF 1933 ITAMAR MEDICAL LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant?s name into Engl |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| November 18, 2021 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPATTM Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, November 18, 2021- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into t |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number 001-38775 ITAMAR MEDICAL LTD. (Translation of Registrant?s name into English) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive off |
|
| October 14, 2021 |
Exhibit 99.1 ITAMAR MEDICAL LTD. NOTICE OF SPECIAL AND 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 16, 2021 To the Shareholders of Itamar Medical Ltd. Notice is hereby given that the Special and 2021 Annual General Meeting of Shareholders (the ?Meeting?) of Itamar Medical Ltd. (?we,? ?Itamar? or the ?Company?) will be held on Tuesday, November 16, 2021, at 1:00 PM (Israel ti |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number 001-38775 ITAMAR MEDICAL LTD. (Translation of registrant?s name into English) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office |
|
| October 14, 2021 |
ITAMAR MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.2 ITAMAR MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Joseph Tenne, Mr. Yaniv Hod and Ms. Noa Farkas Gluck, or either of them, attorneys or attorney of the undersigned, for and in the names(s) of the undersigned, with power of substitution and revocation in each to vote any and all ordinary shares, par value NIS 0.01 per sh |
|
| October 14, 2021 |
Exhibit 99.3 Special and 2021 Annual General Meeting of Shareholders of Itamar Medical Ltd. Date: November 16, 2021 See Voting Instruction On Reverse Side. Please make your marks like this: ? Use pen only 1. To approve the acquisition of the Company by ZOLL Medical Corporation (?Parent?), including the approval of: (i) the Agreement and Plan of Merger, dated September 13, 2021 (as it may be amende |
|
| October 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-38775 ITAMAR MEDICAL LTD. (Translation of registrant?s name into English) ITAMAR MEDICAL LTD. 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive |
|
| October 12, 2021 |
Exhibit 99.1 ITAMAR MEDICAL LTD. NOTICE OF SPECIAL AND 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 16, 2021 To the Shareholders of Itamar Medical Ltd. Notice is hereby given that the Special and 2021 Annual General Meeting of Shareholders (the ?Meeting?) of Itamar Medical Ltd. (?we,? ?Itamar? or the ?Company?) will be held on Tuesday, November 16, 2021, at 1:00 PM (Israel ti |
|
| October 4, 2021 |
PAYX / Paychex, Inc. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437101 (CUSIP Number) September 14, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| September 13, 2021 |
Exhibit 99.1 ZOLL MEDICAL CORPORATION SIGNS DEFINITIVE AGREEMENT TO ACQUIRE ITAMAR MEDICAL Acquiring provider of home sleep apnea diagnosis solutions will allow ZOLL to better serve undiagnosed and untreated cardiac patients September 13, 2021 ? Chelmsford, MA and Caesarea, Israel ? ZOLL? Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check m |
|
| September 13, 2021 |
Exhibit 99.2 [Final Form] VOTING AND SUPPORT AGREEMENT VOTING AND SUPPORT AGREEMENT (this ?Support Agreement?), dated as of [?], 2021, by and between ZOLL Medical Corporation, a Massachusetts corporation (?Parent?), and [?] (?Shareholder?). W I T N E S S E T H WHEREAS, concurrently with the execution and delivery of this Support Agreement, Itamar Medical Ltd., a company organized under the laws of |
|
| September 13, 2021 |
Exhibit 99.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among ZOLL Medical Corporation Zeus Merger Sub Ltd., Asahi Kasei Corporation and Itamar Medical Ltd. dated as of September 13, 2021 TABLE OF CONTENTS Page Article I. THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Closing 1 Section 1.3 Effective Time 1 Section 1.4 Effect of the Merger 1 Section 1.5 Memorandum and Articles of Asso |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check m |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| August 12, 2021 |
Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation August 2021 Exhibit 99.1 Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation August 2021 Disclaimer 2 Itamar Medical Ltd . (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct |
|
| August 12, 2021 |
Itamar Medical Ltd., investors presentation, August 2021. Exhibit 99.1 Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation August 2021 Disclaimer 2 Itamar Medical Ltd . (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| August 12, 2021 |
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors Exhibit 99.1 Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors CAESAREA, Israel, August 12, 2021 - Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| August 10, 2021 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, August 10, 2021- Itama |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3079833, Israel (Address of principal executive office) Indicate by check mark |
|
| July 28, 2021 |
Exhibit 99.1 Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021 CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) - Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark w |
|
| June 17, 2021 |
Exhibit 1 [Unofficial Translation] December 12, 2019 Powers of Signature in The Phoenix Holdings Ltd. |
|
| June 17, 2021 |
PAYX / Paychex, Inc. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437101 (CUSIP Number) June 8, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| May 28, 2021 |
EXHIBIT 1.01 Conflict Minerals Report of Itamar Medical Ltd. For the Year Ended December 31, 2020 Pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 This Conflict Minerals Report is filed as Exhibit 1.01 on Itamar Medical Ltd. Specialized Disclosure Report on Form SD and is also posted on the Itamar Medical Ltd.?s website. 1. Introduction The Democratic Republic of the Congo (?DRC?) |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Itamar Medical Ltd. (Exact name of Registrant as Specified in its Charter) Israel 001-38755 n/a (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 9 Halamish Street, Caesarea 3079883, Israel n/a (Address of principal executive offices) |
|
| May 24, 2021 |
Itamar Medical Appoints Brad Fluegel to its Board of Directors Exhibit 99.1 Itamar Medical Appoints Brad Fluegel to its Board of Directors CAESAREA, Israel, May 24, 2021 - Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel?s vast experien |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 20, 2021 |
Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation May 2021 Exhibit 99.1 Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation May 2021 Disclaimer 2 Itamar Medical Ltd . (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct the |
|
| May 19, 2021 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS FIRST QUARTER 2021 RESULTS - First Quarter 2021 Revenues Increase 43% to $12.0 Million - - U.S. WatchPATTM Revenues Increase 38% to $8.4 Million ? - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, May 19, 2021- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integ |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 5, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 5, 2021 |
Exhibit 99.1 Itamar Medical to Report First Quarter Financial Results and Host Conference Call on Wednesday, May 19, 2021 CAESAREA, Israel, May 5, 2021 (GLOBE NEWSWIRE) - Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its |
|
| March 29, 2021 |
Consent of Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International. Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors Itamar Medical Ltd. We consent to the incorporation by reference in the registration statements (Nos. 333- 250155 and 333-252364) on Form F-3 and (Nos. 333-230799 and 333-236883) on Form S-8 of Itamar Medical Ltd. of our report dated March 29, 2021, with respect to the consolidated statements of financial |
|
| March 29, 2021 |
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F for the fiscal year ended December 31, 2020 of Itamar Medical Ltd. (the ?Company?) as filed with the U.S. Securities and Exchange Commission on the date hereof (the ?Report?) and pursuant to 18 U.S.C. Section 1350, as |
|
| March 29, 2021 |
Exhibit 12.1 CERTIFICATION I, Gilad Glick, certify that: 1. I have reviewed this annual report on Form 20-F of Itamar Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to t |
|
| March 29, 2021 |
Israeli Equity Incentive Plan 2016, as amended on March 1, 2021. Exhibit 4.3 Itamar Medical Ltd. ISRAELI EQUITY INCENTIVE PLAN 2016 As adopted by the Board of Directors on January 21, 2016 1. Purpose This Itamar Medical Ltd. 2016 Equity Incentive Plan (the "Plan") is intended to promote the interests of Itamar Medical Ltd. (the ?Company?) and its shareholders by providing employees, directors, officers, and advisors of the Company or any Affiliate with appropri |
|
| March 29, 2021 |
Exhibit 12.2 CERTIFICATION I, Shy Basson, certify that: 1. I have reviewed this annual report on Form 20-F of Itamar Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to th |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 29, 2021 |
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F for the fiscal year ended December 31, 2020 of Itamar Medical Ltd. (the ?Company?) as filed with the U.S. Securities and Exchange Commission on the date hereof (the ?Report?) and pursuant to 18 U.S.C. Section 1350, as |
|
| March 29, 2021 |
2016 U.S. Equity Incentive Plan, as amended on March 1, 2021. Exhibit 4.4 Itamar Medical Ltd. 2016 U.S. Equity Incentive Plan Adopted By The Board Of Directors: January 21, 2016 Approved By The Shareholders: March 16, 2016 Termination Date: January 20, 2026 1. General. (a) Eligible Share Award Recipients. The persons eligible to receive Share Awards are Employees, Directors, and Consultants. (b) Available Share Awards. The Plan provides for the grant of the |
|
| March 4, 2021 |
Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation March 2021 Exhibit 99.1 Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation March 2021 Disclaimer 2 Itamar Medical Ltd . (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct t |
|
| March 4, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| March 2, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| March 2, 2021 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2020 REVENUES - Record Fourth Quarter 2020 Revenues Increase 31% to $12.8 Million - - U.S. WatchPATTM Revenues Increase 39% to $10.2 Million ? -Full Year 2021 Revenue Guidance of $52 Million and $53 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, March 2, 2021 ? Itamar Medical Lt |
|
| February 16, 2021 |
Exhibit 99.1 Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation February 2021 Disclaimer 2 Itamar Medical Ltd . (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduc |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Ordinary Shares of Itamar Medical Ltd., which may be deemed necessa |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 ITAMAR MEDICAL LTD (Name of Issuer) Ordinary Shares (Title of Class of Securities) 465437101 (CUSIP |
|
| February 16, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) Itamar medical ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 ITAMAR MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS |
|
| February 12, 2021 |
SC 13G Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Itamar Medical LTD. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 per share (Title of Class of Securities) 465437 10 1 (CUSIP Number) October 27, 2020 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 8, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| February 8, 2021 |
EX-1.1 2 tm213913d7ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 UNDERWRITING AGREEMENT February 5, 2021 PIPER SANDLER & CO. COWEN AND COMPANY, LLC SVB LEERINK LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Leerink LLC 1301 Avenu |
|
| February 8, 2021 |
TABLE OF CONTENTS Filed pursuant to Rule 424b5 Registration No. 333-250155 and 333-252364 PROSPECTUS SUPPLEMENT (To Prospectuses dated December 2, 2020 and January 29, 2021) 3,049,130 American Depositary Shares ITAMAR MEDICAL LTD. Representing Ordinary Shares This is an offering of 3,049,130 American Depositary Shares, or ADSs, each representing 30 ordinary shares, par value NIS 0.01 per share, |
|
| February 8, 2021 |
TABLE OF CONTENTS Filed pursuant to Rule 424b5 Registration No. 333-250155 and 333-252364 PROSPECTUS SUPPLEMENT (To Prospectuses dated December 2, 2020 and January 29, 2021) 3,049,130 American Depositary Shares ITAMAR MEDICAL LTD. Representing Ordinary Shares This is an offering of 3,049,130 American Depositary Shares, or ADSs, each representing 30 ordinary shares, par value NIS 0.01 per share, |
|
| February 8, 2021 |
Itamar Medical Announces Pricing of Public Offering of American Depositary Shares Exhibit 99.1 Itamar Medical Announces Pricing of Public Offering of American Depositary Shares CAESAREA, Israel, February 5, 2021 - Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced t |
|
| February 5, 2021 |
Itamar Medical Announces Proposed Offering of American Depositary Shares Exhibit 99.1 Itamar Medical Announces Proposed Offering of American Depositary Shares CAESAREA, Israel, February 4, 2021 - Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the commen |
|
| February 5, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| February 4, 2021 |
Subject to completion, dated February 4, 2021 424B2 1 tm213913-4424b2.htm 424B2 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectuses are part of effective registration statements filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying base prospectuses a |
|
| February 4, 2021 |
Subject to completion, dated February 4, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 27, 2021 |
Itamar Medical Ltd. 9 Halamish Street Caesarea 3088900 Israel January 27, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Dillon Hagius Re: Itamar Medical Ltd. Registration Statement on Form F-3 (File No. 333-252364) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of |
|
| January 27, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| January 27, 2021 |
Itamar Medical Appoints Scott P. Serota to its Board of Directors Exhibit 99.1 Itamar Medical Appoints Scott P. Serota to its Board of Directors CAESAREA, Israel, January 27, 2021 - Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Scott P. Serota to its Board of Directors. Mr. Serota’s vast |
|
| January 25, 2021 |
TABLE OF CONTENTS Filed with the Securities and Exchange Commission on January 22, 2021 Registration No. |
|
| January 7, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| January 7, 2021 |
Exhibit 99.1 Itamar Medical Announces Preliminary Revenue Results for Fourth Quarter and Full Year 2020 - 2020 Fourth Quarter Revenues Expected to Increase More Than 28% to $12.5-$12.8 million - - - 2020 Fiscal Year Revenues Expected to Increase Approximately 31% to $40.8-$41.1 million - - CAESAREA, Israel, January 7, 2021 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a leading medical device |
|
| November 30, 2020 |
Itamar Medical Ltd. 9 Halamish Street Caesarea 3088900 Israel November 30, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Gabor Re: Itamar Medical Ltd. Registration Statement on Form F-3 (File No. 333-250155) Ladies and Gentlemen: In accordance with Rule 461 of under the Se |
|
| November 24, 2020 |
PAYX / Paychex, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 18, 2020 |
Exhibit 1.2 Itamar Medical Ltd. American Depositary Shares Each Representing Thirty Ordinary Shares (par value NIS 0.01 per share) SALES AGREEMENT November 17, 2020 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Itamar Medical Ltd., a company limited by shares organized under the laws of the State of Israel (the ?Company?), confirms its agree |
|
| November 18, 2020 |
Filed with the Securities and Exchange Commission on November 17, 2020 TABLE OF CONTENTS Filed with the Securities and Exchange Commission on November 17, 2020 Registration No. |
|
| November 18, 2020 |
Exhibit 10.1 to our Registration Statement on Form F-3 filed with the SEC on November 18, 2020 Exhibit 10.1 Date: August 11, 2020 The Customer?s Name: ITAMAR MEDICAL LTD (the ?Borrower? or the ?Company?) Address: Halamish 9, Caesarea 3088900 Account No: 250888 in Orot Shopping Mall Branch (the ?Account?) To: BANK MIZRAHI TEFAHOT LTD (the ?Bank?) Dear Sir/Madam Re: CREDIT AGREEMENT We are putting in writing what has been agreed between us regarding the credit facilities and loans that you wi |
|
| November 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| November 17, 2020 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS RECORD THIRD QUARTER 2020 REVENUES - Third Quarter Revenues Increase 36% to $11.0 Million - - U.S. WatchPATTM Revenues Increase 55% to $8.9 Million – -Full Year 2020 Revenue Guidance of $39.5 Million to $40.5 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, November 17, 2020 – Itamar Medical Ltd. (Nasdaq and TASE: I |
|
| November 17, 2020 |
Exhibit 99.2 OPERATING RESULTS AND FINANCIAL REVIEW IN CONNECTION WITH THE UNAUDITED INTERIM CONDENSED CONSOLIDTAED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited interim condensed consolidated financial statements as of and for the nine mo |
|
| November 17, 2020 |
ITAMAR MEDICAL LTD. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Exhibit 99.1 ITAMAR MEDICAL LTD. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Interim Unaudited Consolidated Financial Statements as of September 30, 2020 and for the Three and Nine Months Ended September 30, 2020 and 2019 Unaudited Condensed Consolidated Interim Statements of Financial Position F-2 Unaudited Condensed Consolidated Interim Statements of Operations F- |
|
| November 17, 2020 |
our Current Report on Form 6-K furnished with the SEC on November 17, 2020; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| November 3, 2020 |
Exhibit 99.1 Itamar Medical to Report Third Quarter Financial Results and Host Conference Call on Tuesday, November 17, 2020 CAESAREA, Israel, November 3, 2020 (GLOBE NEWSWIRE) - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep dis |
|
| November 3, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| October 19, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| October 19, 2020 |
Itamar Medical Announces Appointment of Shane Brown as President – U.S. Exhibit 99.1 Itamar Medical Announces Appointment of Shane Brown as President – U.S. CAESAREA, Israel, October 19, 2020 - Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, today announced that Shane Brown has been appointed President – U.S., effective immediately. In the ne |
|
| October 13, 2020 |
Exhibit 99.1 Itamar™ Medical Announces Third Quarter Preliminary Revenue Results and Reinstates Revenue Guidance for Full Year 2020 Q3 Total Revenue Results of $10.7M to $11.0M, reflecting growth of 32%-36% Q3 U.S. WatchPAT Revenue Results of $8.6M to $8.9M, reflecting growth of 51%-56% Full Year 2020 Revenue Guidance of $39.5M to $40.5M CAESAREA, Israel, October 13, 2020 - Itamar Medical Ltd. (Na |
|
| October 13, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| August 20, 2020 |
Current Report of Foreign Issuer - 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| August 20, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| August 13, 2020 |
Exhibit 99.1 Revolutionizing the way sleep disorders are diagnosed and managed Investor Presentation August 13, 2020 Disclaimer 2 Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to co |
|
| August 13, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| August 11, 2020 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS - Second Quarter Revenues Increase 21% to $8.9 Million - - U.S. WatchPATTM Revenues Increase 31% to $6.6 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, August 11, 2020- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical technology company focused on the development and com |
|
| August 11, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| July 27, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark w |
|
| July 27, 2020 |
Exhibit 99.1 Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 11, 2020 CAESAREA, Israel, July 27, 2020 (GLOBE NEWSWIRE) - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorde |
|
| July 15, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark w |
|
| July 15, 2020 |
Exhibit 99.1 July 15, 2020 Dear Shareholder, You are cordially invited to attend the 2020 Annual Meeting of Shareholders (the “Annual Meeting” or the “Meeting”) of Itamar Medical Ltd. (“we”, “Itamar Medical” or the “Company”), to be held on Wednesday, August 19, 2020, at 3:00 p.m. (Israel time). The Meeting will be held at our executive offices at 9 Halamish Street, Caesarea 3088900, Israel. Howev |
|
| July 15, 2020 |
EX-99.2 3 tm2024655d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Annual General Meeting of Shareholders of Itamar Medical Ltd. to be Held on August 19, 2020 for Holders as of July 20, 2020 Annual General Meeting of Shareholders of Itamar Medical Ltd. Date: August 19, 2020 See Voting Instruction On Reverse Side. Please make your marks like this: x Use pen only To reelect the following directors until the |
|
| June 1, 2020 |
Itamar Medical ™ Investor Presentation May 2020 Exhibit 99.1 Itamar Medical ™ Investor Presentation May 2020 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection |
|
| June 1, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark w |
|
| May 27, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 27, 2020 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS - First Quarter 2020 Revenues Increase 38% to $8.4 Million - - WatchPAT™ Revenues Increase 41% to $8.2 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, May 27, 2020- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical technology company focused on the development and commercia |
|
| May 4, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 4, 2020 |
Exhibit 99.1 Itamar Medical Receives CE Mark Approval for its WatchPAT™ ONE, the First Fully Disposable Home Sleep Apnea Test Complete, home-based solution for diagnosing respiratory sleep disorders approved for commercialization in Europe and other CE Mark geographies CAESAREA, Israel, May 4, 2020 - Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology company focused on the developme |
|
| April 20, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| April 20, 2020 |
Itamar Medical ™ Investor Presentation April 2020 Exhibit 99.1 Itamar Medical ™ Investor Presentation April 2020 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connectio |
|
| April 13, 2020 |
Exhibit 99.1 Itamar™ Medical Announces First Quarter 2020 Preliminary Revenue Increase of Approximately 40% - Company Ramping Up WatchPAT™ ONE Production Capacity to Meet Demand for Disposable Home Sleep Apnea Tests - CAESAREA, Israel, April 13, 2020 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medi |
|
| April 13, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| April 3, 2020 |
Consent of Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International. EX-15.1 10 tm206812d1ex15-1.htm EXHIBIT 15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors Itamar Medical Ltd. We consent to the incorporation by reference in the registration statements (Nos. 333-230799 and 333-236883) on Form S-8 of Itamar Medical Ltd. of our report dated March 30, 2020, with respect to the consolidated statements of financial posit |
|
| April 3, 2020 |
Exhibit 2.6 DESCRIPTION OF THE RIGHTS OF EACH CLASS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Itamar Medical Ltd. had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or Exchange Act: our ordinary shares and our American Depositary Shares, or ADSs. References herein to “we,” “us |
|
| April 3, 2020 |
Exhibit 12.2 CERTIFICATION I, Shy Basson, certify that: 1. I have reviewed this annual report on Form 20-F of Itamar Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to th |
|
| April 3, 2020 |
Exhibit 12.1 CERTIFICATION I, Gilad Glick, certify that: 1. I have reviewed this annual report on Form 20-F of Itamar Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to t |
|
| April 3, 2020 |
Exhibit 4.12 [INFORMAL ENGLISH TRANSLATION] Date: February 9, 2020 Name of the customer: Itamar Medical Ltd. (hereinafter: the “Borrower” or the “Company” or the “Customer”) Company No. 512434218 Address: 9 Halamish Street, Caesarea 3088900 Account number: 250888 in the Orot Mall Branch (hereinafter: the “Account”) To: Mizrahi Tefahot Bank Ltd. (hereinafter: the “Bank”) To Whom It May Concern: Re: |
|
| April 3, 2020 |
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F for the fiscal year ended December 31, 2019 of Itamar Medical Ltd. (the “Company”) as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”) and pursuant to 18 U.S.C. Section 1350, as |
|
| April 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 3, 2020 |
Warrant extension agreement by and between the Registrant and Mizrahi, dated February 9, 2020. Exhibit 2.4/A February 9, 2020 To: Mizrahi Tefahot Bank Ltd. (“Holder”) Dear Holder, RE: EXTENSION OF PREVIOUS WARRANTS Itamar Medical Ltd. (hereinafter: the “Company”) currently intends to enter into an amendment to the framework agreement with Holder, under which the existing framework agreement shall be extended, and certain additional terms shall be amended. In the framework of the negotiation |
|
| April 3, 2020 |
Warrant Agreement by and between the Registrant and Mizrahi, dated as of February 9, 2020. Exhibit 2.5 WARRANT AGREEMENT This Warrant Agreement (the “Agreement”), is made as of the 9 day of February, 2020 (the "Effective Date") by and between: (1) Itamar Medical Ltd. (the “Company”), an Israeli public company (Company No. 51-243421-8), whose shares are traded on the Tel-Aviv Stock Exchange (“TASE”); and (2) Mizrahi Tefahot Bank Ltd. (the “Bank”), an Israeli Company formed under the laws |
|
| April 3, 2020 |
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F for the fiscal year ended December 31, 2019 of Itamar Medical Ltd. (the “Company”) as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”) and pursuant to 18 U.S.C. Section 1350, as |
|
| March 20, 2020 |
Itamar™ Medical Implements Broad Range of Actions in Response to COVID-19 Pandemic Exhibit 99.1 Itamar™ Medical Implements Broad Range of Actions in Response to COVID-19 Pandemic CAESAREA, Israel, March 20, 2020 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today released the following letter from its President |
|
| March 20, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| March 19, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| March 12, 2020 |
Exhibit 99.1 APPENDIX A Amendments to Compensation Policy Itamar Medical Ltd. (The "Company") Compensation Policy As approved by the Company's Compensation Committee on March 10, 2019 By the Company's Board of Directors on March 12, 2019 And by the Company's Shareholders at a Meeting of the Shareholders on May 29 2019 The definitions and terms in this Compensation Policy shall have the definitions |
|
| March 12, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| March 4, 2020 |
ITMMF / Itamar Medical, Ltd. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on March 4, 2020 Registration No. |
|
| March 3, 2020 |
Exhibit 99.1 ITAMAR™ MEDICAL REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2019 REVENUES - Record Fourth Quarter 2019 Revenues Increase 48% to $9.8 Million - - Reaffirms Full Year 2020 Revenue Guidance of between $39.5 Million and $42.0 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, March 3, 2020- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a med |
|
| March 3, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| February 18, 2020 |
PAYX / Paychex, Inc. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 18, 2020 |
Exhibit 3 [Unofficial Translation] December 12, 2019 Powers of Signature in The Phoenix Holdings Ltd. |
|
| February 12, 2020 |
TLV:ITMR / ITAMAR / Viola Growth Management Fund 2 Ltd. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (including Ordinary Shares represented by American Depositary Shares, at |
|
| February 12, 2020 |
EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Statement on Schedule 13G filed herewith, and any amendments thereto filed hereafter by any of the undersigned parties, relating to the ordinary shares, par value NIS 0.01 per share (including ordinary shares represented by American Depositary Shares (each American Depositary Share repres |
|
| February 11, 2020 |
Itamar Medical Ltd. NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 18, 2020 Exhibit 99.1 February 11, 2020 Dear Shareholder, You are cordially invited to attend the Special General Meeting of Shareholders (the “General Meeting” or the “Meeting”) of Itamar Medical Ltd. (“we”, “Itamar Medical” or the “Company”), to be held at our executive offices at 9 Halamish Street, Caesarea 3088900, Israel, on Wednesday, March 18, 2020, at 4:00 p.m. (Israel time). At the General Meeting |
|
| February 11, 2020 |
PAYX / Paychex, Inc. / YARON GIORA - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 ITAMAR MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.0 |
|
| February 11, 2020 |
ITAMR MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.2 ITAMR MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Mr. Joseph Tenne and Mr. Yaniv Hod, or either of them, attorneys or attorney of the undersigned, for and in the names(s) of the undersigned, with power of substitution and revocation in each to vote any and all ordinary shares, par value NIS 0.01 per share (“Ordinary Shares”) |
|
| February 11, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| February 10, 2020 |
PAYX / Paychex, Inc. / Yelin Lapidot Holdings Management Ltd. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437101 (CUSIP Number) January 28, 2020 (1)(2) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 6, 2020 |
PAYX / Paychex, Inc. / Migdal Insurance & Financial Holdings Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 ITAMAR MEDICAL LTD (Name of Issuer) Ordinary Shares (Title of Class of Securities) 465437101 (CUSIP |
|
| January 31, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| January 31, 2020 |
ItamarTM Medical Announces Upsizing and Pricing of Public Offering of American Depositary Shares Exhibit 99.1 ItamarTM Medical Announces Upsizing and Pricing of Public Offering of American Depositary Shares CAESAREA, Israel, January 30, 2020 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the upsizing and prici |
|
| January 31, 2020 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-236120 Prospectus 2,545,450 American Depositary Shares Itamar Medical Ltd. Representing Ordinary Shares We are offering 2,545,450 American Depositary Shares, or ADSs, through the underwriters named in the prospectus. Each ADS represents 30 ordinary shares. ADSs representing our ordinary shares are quoted on the Nasdaq Capita |
|
| January 30, 2020 |
ITMMF / Itamar Medical, Ltd. F-1MEF - - F-1MEF As filed with the Securities and Exchange Commission on January 30, 2020 Registration No. |
|
| January 29, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 29, 2020 Registration No. |
|
| January 28, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| January 28, 2020 |
ITMMF / Itamar Medical, Ltd. CORRESP - - Itamar Medical Ltd. 9 Halamish Street Caesarea 3088900, Israel January 28, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Irene Paik Re: Itamar Medical Ltd. Registration Statement on Form F-1 CIK No. 0001613170 Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of th |
|
| January 28, 2020 |
ItamarTM Medical Announces Proposed $30 Million Offering of American Depositary Shares Exhibit 99.1 ItamarTM Medical Announces Proposed $30 Million Offering of American Depositary Shares CAESAREA, Israel, January 28, 2020 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the commencement of a proposed $ |
|
| January 28, 2020 |
ITMMF / Itamar Medical, Ltd. CORRESP - - January 28, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 28, 2020 |
2007 Israeli Share Option Plan. Exhibit 10.4 Itamar Medical Ltd. 2007 ISRAELI SHARE OPTION PLAN 1. PURPOSE The purpose of this Share Option Plan is to secure for Itamar Medical Ltd. and its shareholders the benefits arising from ownership of share capital by employees, officers directors and consultants of the Company and its Affiliates (as defined below), who are expected to contribute to the Company's future growth and success |
|
| January 28, 2020 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT [•], 2020 PIPER SANDLER & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Itamar Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto ( |
|
| January 28, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 28, 2020 Registration No. |
|
| January 28, 2020 |
Exhibit 10.15 1 1 . T H I S I T E M O N L Y A P P L I E S T O A M E N D M E N T S O F S O L I C I T A T I O N S Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy |
|
| January 28, 2020 |
Lease Agreement, dated July 8, 2019, by and between the Registrant and Willer Properties (1985) Ltd. Exhibit 10.11 Rental agreement Between : Willer Properties (1985) Ltd. and : Itamar Medical Ltd. Rubber stamp and signature : Itamar Medical Ltd., Signatures in initials : M. B. And G. G. (-) Addendums : addendum A : Technical specifications and sketch addendum B : the rental period addendum C : promissory note addendum D : text of the bank guarantee addendum E : owner guarantee addendum F : accou |
|
| January 28, 2020 |
Exhibit 10.13 In compliance with Regulation S-K Item 601(b)(10)(iv), certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed CONTRACT NO. 5881 MASTER PRODUCTS AND SERVICES AGREEMENT This MASTER PRODUCTS AND SERVICES AGREEMENT ("Agreement") is made and entered into as of this 1 |
|
| January 28, 2020 |
Compensation Policy for Executive Officers and Directors, as amended on May 29, 2019. Exhibit 10.9 APPENDIX A Amendments to Compensation Policy Itamar Medical Ltd. (The "Company") Compensation Policy As approved by the Company's Compensation Committee on March 10, 2019 By the Company's Board of Directors on March 12, 2019 And by the Company's Shareholders at a Meeting of the Shareholders on May 29 2019 The definitions and terms in this Compensation Policy shall have the definitions |
|
| January 17, 2020 |
Itamar Medical ™ Investor Presentation January 2020 Exhibit 99.1 Itamar Medical ™ Investor Presentation January 2020 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connect |
|
| January 17, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| January 15, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| January 14, 2020 |
ITMMF / Itamar Medical, Ltd. DRS - - TABLE OF CONTENTS Confidential Treatment Requested by Itamar Medical Ltd. Pursuant to 17 CFR 200.83 As confidentially submitted to the Securities and Exchange Commission on January 14, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ITAMAR MEDICAL LTD. (EXACT NAME OF REGISTRANT |
|
| January 14, 2020 |
Exhibit 10.15 1 1 . T H I S I T E M O N L Y A P P L I E S T O A M E N D M E N T S O F S O L I C I T A T I O N S Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy |
|
| January 14, 2020 |
Exhibit 10.13 In compliance with Regulation S-K Item 601(b)(10)(iv), certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed CONTRACT NO. 5881 MASTER PRODUCTS AND SERVICES AGREEMENT This MASTER PRODUCTS AND SERVICES AGREEMENT ("Agreement") is made and entered into as of this 1 |
|
| January 14, 2020 |
Exhibit 10.9 APPENDIX A Amendments to Compensation Policy Itamar Medical Ltd. (The "Company") Compensation Policy As approved by the Company's Compensation Committee on March 10, 2019 By the Company's Board of Directors on March 12, 2019 And by the Company's Shareholders at a Meeting of the Shareholders on May 29 2019 The definitions and terms in this Compensation Policy shall have the definitions |
|
| January 14, 2020 |
Itamar Medical Ltd. 2007 ISRAELI SHARE OPTION PLAN Exhibit 10.4 Itamar Medical Ltd. 2007 ISRAELI SHARE OPTION PLAN 1. PURPOSE The purpose of this Share Option Plan is to secure for Itamar Medical Ltd. and its shareholders the benefits arising from ownership of share capital by employees, officers directors and consultants of the Company and its Affiliates (as defined below), who are expected to contribute to the Company's future growth and success |
|
| January 13, 2020 |
Exhibit 99.1 Itamar™ Medical Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 and Revenue Guidance for Full Year 2020 - 2019 Fiscal Year Revenues Expected to Increase 29% to $31.1 Million to $31.3 Million - - Full Year 2020 Revenue Guidance of $39.5 Million to $42.0 Million - CAESAREA, Israel, January 13, 2020 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that dev |
|
| January 13, 2020 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| December 11, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| December 11, 2019 |
Itamar Medical ™ Investor Presentation December 2019 Exhibit 99.1 Itamar Medical ™ Investor Presentation December 2019 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connec |
|
| December 4, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| December 3, 2019 |
Itamar Medical ™ Investor Presentation December 2019 Exhibit 99.1 Itamar Medical ™ Investor Presentation December 2019 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connec |
|
| December 3, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| November 26, 2019 |
Exhibit 99.1 ITAMAR™ MEDICAL REPORTS RECORD THIRD QUARTER 2019 REVENUES - Third Quarter Revenues Increase 33% to $8.1 Million - - WatchPATTM Revenues Increase 32% in the Third Quarter to $7.6 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, November 26, 2019 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and m |
|
| November 26, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| November 14, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| November 4, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| October 31, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| October 23, 2019 |
Itamar Medical Appoints Jennifer Cook, MD, FAHA, FACC, as Global Medical Director Exhibit 99.1 Itamar Medical Appoints Jennifer Cook, MD, FAHA, FACC, as Global Medical Director CAESAREA, Israel, October 23, 2019 – Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management w |
|
| October 23, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mar |
|
| September 12, 2019 |
ITMMF / Itamar Medical, Ltd. / MEITAV DASH INVESTMENTS LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2 )* ITAMAR MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437 101 (CUSIP Number) September 11, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| August 22, 2019 |
Itamar Medical Investor Presentation August 2019 Exhibit 99.1 Itamar Medical Investor Presentation August 2019 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection |
|
| August 22, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| August 14, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| August 14, 2019 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS RECORD SECOND QUARTER 2019 REVENUES - Total Second Quarter Revenues Increase 21% to $7.4 Million - - WatchPATTM Revenues Increase 16% in the Second Quarter to $6.5 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, August 14, 2019 - Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures |
|
| August 8, 2019 |
ITMMF / Itamar Medical, Ltd. / Ms Pace Lp - SC 13G AMENDMENT NO. 1 Passive Investment SC 13G Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Itamar Medical LTD. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 per share (Title of Class of Securities) 465437 10 1 (CUSIP Number) February 26, 2019 (1) (Date of Event Which Requires Filing of this Statement) Check the |
|
| July 31, 2019 |
EX-99.A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a Schedule 13G (including amendments thereto) relating to the beneficial ownership of common stock of Itamar Medical LTD, and further agree that this Joint Filing Agreement be included as an |
|
| July 31, 2019 |
ITMMF / Itamar Medical, Ltd. / Ms Pace Lp - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Itamar Medical LTD (Name of Issuer) American Depositary Shares* (Title of Class of Securities) 465437 10 1** (CUSIP Number) February 26, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| June 26, 2019 |
Exhibit 3 [Unofficial Translation] January 30, 2018 Powers of Signature in The Phoenix Holdings Ltd. |
|
| June 26, 2019 |
Notice of resolution of the Board of Directors of Delek Group Ltd., dated as of February 7, 2018. Exhibit 2 Delek Group Ltd 7.2.2018 To whom it may concern Re: Delek Group Ltd, 520044322 (hereinafter: "The Company") I, the undersigned Meital Avital Ratzon, an Advocate and a member of the Legal Department of the Company, hereby certify that: ***, Mr. Gabi Last, Mrs. Leora Pratt Levin, *** and ***, are elected signatories of the Company, and any 2 (two) of these individuals on and above the Comp |
|
| June 26, 2019 |
Agreement of Joint Filing by and among the Reporting Persons, dated as of June 26, 2019. Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Ordinary Shares of Itamar Medical Ltd. |
|
| June 26, 2019 |
ITMMF / Itamar Medical, Ltd. / Phoenix Holdings Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437101 (CUSIP Number) June 20, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| June 25, 2019 |
ITMMF / Itamar Medical, Ltd. / MEITAV DASH INVESTMENTS LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1 )* ITAMAR MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437 101 (CUSIP Number) March 31, 20191 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| June 19, 2019 |
ITMMF / Itamar Medical, Ltd. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on June 19, 2019 Registration No. |
|
| June 6, 2019 |
Exhibit 99.1 Itamar Medical’s WatchPAT™ One, the First and Only Fully Disposable Home Sleep Apnea Test Receives FDA 510(k) Clearance New system expands WatchPAT access to additional sleep centers by reducing infrastructure needs and eliminating capital requirements; also reduces infection risk for in-patient sleep apnea testing CAESAREA, Israel, June 6, 2019 - Itamar Medical Ltd. (Nasdaq & TASE: I |
|
| June 6, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark w |
|
| May 29, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 24, 2019 |
Exhibit 99.1 APPENDIX A Amendments to Compensation Policy (Changes shown: proposed new text is underlined, text proposed to be deleted is struck-through) Itamar Medical Ltd. (The "Company") Compensation Policy As approved by the Company's Compensation Committee on MarchJanuary 1018, 20196 By the Company's Board of Directors on March 12January 21, 20196 By the Company's Compensation Committee on Ma |
|
| May 24, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 23, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 23, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 23, 2019 |
Exhibit 99.1 Itamar Medical Investor Presentation May 2019 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection wi |
|
| May 21, 2019 |
Exhibit 99.1 ITAMAR MEDICAL REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS - WatchPAT™ Revenues Increase 15% to $5.8 Million - -U.S. WatchPAT Revenues Increase 34% to $4.3 Million – - Total Revenues Increase 11% to $6.1 Million - CAESAREA, Israel, May 21, 2019 - Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sl |
|
| May 21, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| May 7, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K Current Report of Foreign Issuer FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark wh |
|
| April 30, 2019 |
Exhibit 99.1 1.3 Mr. Ilan Biran postage-paid envelope provided. 1.4 Mr. Jonathan Kolber 1.5 Mr. Sami Totah 1.6 Mr. Christopher M. Cleary 2. To reelect the following external directors for a period of 3 years starting All votes must be received prior to 12:00 p.m. EST on May 24, 2019. June 17, 2019. 2.1 Ms. Yaffa Krindel Sieradzki Directors Recommend For additional information, please visit: itamar |
|
| April 30, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K (Current Report of Foreign Issuer) FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| April 23, 2019 |
ITMMF / Itamar Medical, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| April 23, 2019 |
Exhibit 99.2 • Mark, sign and date your Voting Instruction Form. • Detach your Voting Instruction Form. • Return your Voting Instruction Form in the postage-paid envelope provided. MAIL Please Sign Here Please Date Above Please Sign Here Please Date Above Please separate carefully at the perforation and return just this portion in the envelope provided. Authorized Signatures - This section must be |
|
| April 23, 2019 |
Exhibit 99.1 April 23, 2019 Dear Shareholder, You are cordially invited to attend the 2019 Annual Meeting of Shareholders (the “Annual Meeting” or the “Meeting”) of Itamar Medical Ltd. (“we”, “Itamar Medical” or the “Company”), to be held at our executive offices at 9 Halamish Street, Caesarea 3088900, Israel, on Wednesday, May 29, 2019, at 1:00 p.m. (Israel time). At the Annual Meeting, sharehold |
|
| April 23, 2019 |
ITMMF / Itamar Medical, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| April 18, 2019 |
Exhibit 3 [Unofficial Translation] January 30, 2018 Powers of Signature in The Phoenix Holdings Ltd. |
|
| April 18, 2019 |
NNDM / Nano Dimension Ltd / Phoenix Holdings Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Itamar Medical Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437101 (CUSIP Number) April 4, 2019 (1) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| April 18, 2019 |
Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Ordinary Shares of Itamar Medical Ltd. |
|
| April 18, 2019 |
Exhibit 2 Delek Group Ltd 7.2.2018 To whom it may concern Re: Delek Group Ltd, 520044322 (hereinafter: "The Company") I, the undersigned Meital Avital Ratzon, an Advocate and a member of the Legal Department of the Company, hereby certify that: ***, Mr. Gabi Last, Mrs. Leora Pratt Levin, *** and ***, are elected signatories of the Company, and any 2 (two) of these individuals on and above the Comp |
|
| April 15, 2019 |
ITMMF / Itamar Medical, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| April 10, 2019 |
ITMMF / Itamar Medical, Ltd. FORM S-8 As filed with the Securities and Exchange Commission on April 10, 2019 Registration No. |
|
| April 10, 2019 |
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 EXHIBIT 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the Annual Report of Itamar Medical Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Shy Basson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, that, to my knowledge: (1) T |
|
| April 10, 2019 |
Exhibit 4.11 [INFORMAL ENGLISH TRANSLATION] Secured Debenture Signed on the 28th of May, 2017 By Itamar Medical Ltd., Company No. 5124343218, of 9 Halamish Street, Caesarea (hereinafter: the “Company”) For the benefit of Mizrahi Tefahot Bank Ltd. (hereinafter: the “Bank”), pursuant to the incorporation documents of the Company and all of the other provisions that provide the Company with power in |
|
| April 10, 2019 |
EXHIBIT 12.2 CERTIFICATION pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended I, Shy Basson, certify that: 1. I have reviewed this annual report on Form 20-F of Itamar Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li |
|
| April 10, 2019 |
Exhibit 2.4A To March 12, 2019 Mizrahi Tefahot Bank Ltd. ("Holder") Dear Holder, RE: Extension of Previous Warrant Itamar Medical Ltd. (hereinafter: the "Company") currently intends to enter into a framework agreement with Holder. In the framework of the negotiations, and in order to induce Holder to enter into the framework agreement and to extend credit to the Company, Company has agreed to exte |
|
| April 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| April 10, 2019 |
Exhibit 4.16 WARRANT AGREEMENT This Warrant Agreement (the “Agreement”), is made as of the 12th day of March, 2019 (the "Effective Date") by and between: (1) Itamar Medical Ltd. (the “Company”), an Israeli public company (Company No. 51-243421-8), whose shares are traded on the Tel-Aviv Stock Exchange (“TASE”); and (2) Mizrahi Tefahot Bank Ltd. (the “Bank”), an Israeli Company formed under the law |
|
| April 10, 2019 |
Exhibit 4.11A [INFORMAL ENGLISH TRANSLATION] Date: March 12, 2019 Name of the customer: Itamar Medical Ltd. (hereinafter: the “Borrower” or the “Company” or the “Customer”) Company No. 512434218 Address: 9 Halamish Street, Caesarea 3088900 Account number: 250888 in the Orot Mall Branch (hereinafter: the “Account”) To: Mizrahi Tefahot Bank Ltd. (hereinafter: the “Bank”) To Whom It May Concern: Re: |
|
| April 10, 2019 |
EXHIBIT 12.1 CERTIFICATION pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended I, Gilad Glick, certify that: 1. I have reviewed this annual report on Form 20-F of Itamar Medical Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in l |
|
| April 10, 2019 |
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the Annual Report of Itamar Medical Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gilad Glick, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, that, to my knowledge: (1) |
|
| April 8, 2019 |
Itamar Medical Investor Presentation April 2019 Exhibit 99.1 Itamar Medical Investor Presentation April 2019 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection |
|
| April 8, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| April 3, 2019 |
ITMMF / Itamar Medical, Ltd. / MEITAV DASH INVESTMENTS LTD - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ITAMAR MEDICAL LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) 465437 101 (CUSIP Number) March 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| March 19, 2019 |
ITMMF / Itamar Medical, Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv5165396k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive o |
|
| March 19, 2019 |
Exhibit 99.1 Itamar Medical Investor Presentation March 2019 Disclaimer Itamar Medical Ltd . (the " Company ") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection |
|
| March 13, 2019 |
ITMMF / Itamar Medical, Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| March 13, 2019 |
EX-99.1 2 tv516067ex99-1.htm EXHIBIT99.1 Exhibit 99.1 ITAMAR MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS WITH RECORD REVENUES Full Year 2018 Revenues Increased 17% to $24.2 Million; WatchPAT™ Revenues Increased 24% to $22.4 Million Fourth Quarter 2018 Revenues Increased 9% to $6.6 Million; WatchPAT Revenues Increased 19% to $6.0 Million American Depositary Shares (ADSs) Com |
|
| March 12, 2019 |
Itamar Medical to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 Exhibit 99.1 Itamar Medical to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 CAESAREA, Israel, March 12, 2019 – Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that Gilad Glick, Chief Execut |
|
| March 12, 2019 |
ITMMF / Itamar Medical, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| March 7, 2019 |
ITMMF / Itamar Medical, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check mark |
|
| February 28, 2019 |
ITMMF / Itamar Medical, Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission file number: 001-38775 ITAMAR MEDICAL LTD. (Name of registrant) 9 Halamish Street, Caesarea 3088900, Israel (Address of principal executive office) Indicate by check ma |
|
| February 28, 2019 |
Exhibit 99.1 Itamar Medical to Commence Trading on Nasdaq Will Trade on both Nasdaq and TASE under the Ticker Symbol ‘ITMR’ CAESAREA, Israel, February 27, 2019– Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that it will l |
|
| February 25, 2019 |
ITAMAR MEDICAL LTD. 9 Halamish Street Caesarea 3088900, Israel February 25, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Itamar Medical Ltd. (CIK: 0001613170) Registration Statement on Form 20-F Initially Submitted December 31, 2018 File No.: 001-38775 Ladies and Gentlemen: Pursuant to Rule 461 promulg |
|
| February 22, 2019 |
February 22, 2019 VIA EDGAR Russel Mancuso Branch Chief - Legal Division of Corporation Finance Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N. |
|
| February 13, 2019 |
ITMMF / Itamar Medical, Ltd. 20FR12B/A As filed with the Securities and Exchange Commission on February 13, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| February 13, 2019 |
Exhibit 4.10 SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEMS OFFEROR TO COMPLETE BLOCKS 12, 17, & 30 1. REQUISITION NUMBER N/A PAGE 1 OF 1 2. CONTRACT NO. V797D-30190 3. AWARD/EFFECTIVE DATE 06/15/2013 4. ORDER NO. MODIFICATION NO. N/A 5. SOLICITATION NO. RFP-797-FSS-99-0025-R7 6. SOLICITATION ISSUE DATE 4/22/2011 7. FOR SOLICITATION INFORMATION CALL: a. NAME: FEDERAL SUPPLY SCHEDULE HELPDESK b. |
|
| February 13, 2019 |
February 13, 2019 VIA EDGAR Russell Mancuso Branch Chief - Legal Division of Corporation Finance Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N. |
|
| January 30, 2019 |
Exhibit 4.14 EXECUTION COPY SECURITIES PURCHASE AGREEMENT by and among ITAMAR MEDICAL LTD. and THE PURCHASERS IDENTIFIED ON THE SIGNATURE PAGES HERETO January 16, 2019 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 16, 2019, by and among Itamar Medical Ltd., an Israeli company (the “Company”), and each purchaser identified |
|
| January 30, 2019 |
Exhibit 4.15 EXECUTION COPY SECURITIES PURCHASE AGREEMENT by and among ITAMAR MEDICAL LTD. and THE PURCHASERS IDENTIFIED ON THE SIGNATURE PAGES HERETO January 28, 2019 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 28, 2019, by and among Itamar Medical Ltd., an Israeli company (the “Company”), and each purchaser identified |
|
| January 30, 2019 |
As filed with the Securities and Exchange Commission on January 29, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
